SLAS2025

January 25 - 29, 2025

San Diego, CA, USA

Transform Drug Discovery with Cutting-Edge Bruker Technology at SLAS2025!

Register today to explore a comprehensive portfolio of technologies that span more steps in the drug discovery process than ever before—ranging from molecular identity characterization and high-throughput hit screening to dynamic interaction profiling and cellular assays.

 

Unlock new possibilities in single B-cell screening for biologics discovery, harness high-throughput mass spectrometry and Surface Plasmon Resonance for lead identification and development, and achieve groundbreaking insights into molecular interactions with single-cell Interaction Cytometry, enabling kinetic measurements directly on cells.

 

Accelerate your research with the innovative tools trusted by leading scientists and pharmaceutical innovators around the globe.

Event Highlights

  • Meet us at Booth 2027: We're looking forward to meeting you in front of our biosensors, Beacon® and mass spec-based solutions that will be on display at our booth. Take the chance to discuss with our experts how our solutions can help you in current and future projects.
  • Exhibitor tutorials: Attend our tutorial sessions hosted by Bruker's expert team to discover the latest on Bruker’s Biosensors and antibody screening solutions.

Bruker Biosensors Tutorial
Monday, January 27, 2025 
12:00 - 1:15 pm PST

A pipeline to success: Biosensor Tools Enable Next Generation Therapeutic Molecules

Location: Room 24C

Lab automation technologies are transforming biologics development by streamlining the selection and optimization of candidates. However, the complexity of biologics—often involving intricate structures and binding interactions—presents challenges in optimizing pharmacokinetics, efficacy, and safety.

This presentation highlights three advanced automated biophysical tools: high-throughput, multiplexing Surface Plasmon Resonance (SPR) for rapid candidate identification and detailed lead development, switchSENSE® for analyzing avidity effects and multispecific binders, and single-cell Interaction Cytometry for real-time kinetic measurements directly on cells to assess native binding properties.

These tools offer comprehensive profiling to accelerate biologics development by identifying lead candidates with optimal biophysical characteristics and are also applicable to other therapeutic modalities like small molecules.

Speakers

Prof. Ulrich Rant, Ph.D., CSO Bruker Biosensors, Munich, Germany

Prof. Dr. Ulrich Rant received his Ph.D. in biophysics from the Technical University Munich. He is CSO of Bruker Biosensors, Director of the Kurt-Schwabe-Institute for Bioanalytical Systems (KSI) and Professor of Physical Chemistry (Sensors) at Technical University Dresden. In these roles, he is driving the development of technologies in the field of biomolecular interaction analysis and nano-biosensors. 

Cyrill Brunner, Ph.D., Senior Application Scientist, Bruker Switzerland, Fällanden, Switzerland

Dr. Cyrill Brunner is a trained pharmacist and obtained his Ph.D. at ETH Zurich in the group of Prof. Gisbert Schneider. His main background is numerous biophysical assays including SPR and computational drug design. He joined Bruker as an application specialist in April 2020 and heads the SPR application lab in Fällanden, Switzerland.

Bruker Cellular Analysis Tutorial
Monday, January 27, 2025
2:00 - 3:00 pm PST

Advancing Therapeutic Antibody Discovery: High-Throughput Single B Cell Screening for Challenging Targets on the Beacon® Platform

Location: Location: Room 24C

Bruker Cellular Analysis presents innovative solutions for camelid heavy chain-only antibody (HCAb) discovery, specifically for challenging targets, using the Beacon® Optofluidic Platform.

The Beacon® Platform enables rapid, specific antibody identification and offers modular kits that integrate seamlessly with immunization workflows, supporting each stage from initial immunization to final antibody selection. By reducing development time and enhancing discovery success, this end-to-end approach optimizes antibody campaigns.

The session will showcase how Beacon’s microfluidic technology isolates and analyzes single B cells, allowing researchers to efficiently identify rare, high-quality therapeutic antibodies. 

Speaker

Vincent Pai, Director of Product Management at Bruker Cellular Analysis, Emeryville, CA, United States

Vincent Pai is Director of Product Management at Bruker Cellular Analysis. He has over 10 years of experience in cell biology, nanotechnology, and microfluidics, with a background from UC San Diego and Massachusetts General Hospital in Boston. He now leads new product development for antibody discovery applications on the Beacon® optofluidic system.

Disclaimer

As you are certainly aware, special compliance regulations apply to public officials* and healthcare professionals** with regard to the event we are planning. If you accept our invitation, we will therefore assume that you will observe the compliance regulations that apply to you and that you have the necessary employer approval.

*Government Official means according the Bruker policies any of the following: any officer, employee or representative of a government (national, regional or local) entity, or any public agency, public authority, department or instrumentality thereof, regardless of their rank or title (e.g. a regulatory official or government inspector); any person working for or advising a government-owned or government-controlled enterprise (e.g. a professor at a government-owned university, or a purchaser at a government-owned hospital); any person working for or advising a national or international non-governmental organization (e.g. an employee of the Red Cross or The World Bank); any person performing a public function or providing a public service, even if that person works for a non-governmental institution (e.g. private security personnel working in public functions); any person hired to review or accept bids for a government agency; any person with the responsibility to allocate or expend government funds; any person in a public law function, civil servant, judge or military personnel; any person acting for a political party, including party officials, candidates or individuals holding a position in a political party office; members of royal families; or immediate family members of any of the persons listed above. An immediate family member is a grandparent, parent, spouse, significant other, child, or sibling.

**A Healthcare Professional (HCP) is in accordance with the Bruker policies any physician, dentist, nurse, pharmacist or other individual who may prescribe, administer, purchase, dispense, recommend, or supply medical products or treatments or pharmaceutical products. In many cases, Bruker interacts with HCPs who work for state-owned hospitals (e.g. as medical scientists). These individuals will be classified as both HCPs and Government Officials.

 

For Research Use Only. Not for use in clinical diagnostic procedures.